Cabaletta Bio
Cabaletta Bio is a specialist developer of engineered cell therapies for autoimmune diseases. The company is part of a broader movement to apply CAR-T and related cell therapy technologies beyond cancer, especially in diseases where pathogenic immune cells may be reset or depleted.
- Highest 2026 tier: Tier III
- Cell & Gene Therapy Developers
- 1 ranking category
Overview
Cabaletta Bio is a specialist developer of engineered cell therapies for autoimmune diseases. The company is part of a broader movement to apply CAR-T and related cell therapy technologies beyond cancer, especially in diseases where pathogenic immune cells may be reset or depleted.
Cabaletta’s strength lies in therapeutic expansion. If cell therapy can demonstrate durable benefit in autoimmune disease, the market could broaden far beyond hematologic malignancies. This makes the company strategically relevant despite being smaller than commercial CAR-T developers.
Cabaletta Bio is included in 1 2026 ranking category. Its highest classification is Tier III. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | Cabaletta Bio |
| Founded | 2017 |
| Institution type | Cell & Gene Therapy Developers institution |
| Headquarters | Philadelphia, United States |
| Primary focus | Cell & Gene Therapy Developers |
| Highest 2026 ranking tier | Tier III |
Principal activities
Cabaletta’s strength lies in therapeutic expansion. If cell therapy can demonstrate durable benefit in autoimmune disease, the market could broaden far beyond hematologic malignancies. This makes the company strategically relevant despite being smaller than commercial CAR-T developers.
Core capability
Cell & Gene Therapy Developers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Cell & Gene Therapy Developers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Its autoimmune cell therapy platform and disease-expansion potential support its Tier III inclusion.
Cabaletta Bio is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier III.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Cabaletta Bio should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Cabaletta Bio. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Cabaletta Bio |
| Headquarters | Philadelphia, United States |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Cell & Gene Therapy Developers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
